Cannabix: Data Shows THC Detection Technology’s Tremendous Promise


Ryan Allway

March 29th, 2016

News, Top News


[stockchart symbol=BLOZF]

Cannabix Technologies Inc. [stockquote symbol=BLOZF], a leader in marijuana breathalyzer development for law enforcement and the workplace, recently presented at PITTCON 2016 in Atlanta, Georgia, one of the world’s largest annual laboratory science conferences. The company also discusses the FAIMS technology’s ability to detect THC in controlled breath samples with detection that is 10 times more sensitive than previous literature suggested.

Management is working to make a miniaturized version of the FAIMS-MS device for use by law enforcement and workplace officials. Agreements are in place with parts suppliers and the parts required to build the portable version of the device are already on order. The company anticipates that the device will be available for field testing over the coming months.

Read the entire press release here:

Cannabix Technologies Inc. (CSE:BLO)(OTC PINK:BLOZF) (the “Company”) is pleased to provide an update on its technology development and recent presentation at the PITTCON 2016 conference in Atlanta, Georgia. PITTCON is one of the world’s largest annual premier conference and expositions on laboratory science. Cannabix and University of Florida researchers (UF) were invited to present the state of the art technology at sessions focused on drugged driving and illicit drug detection. Dr. Jared Boock gave a talk titled “Detection of Tetrahydrocannabinol (THC) and Related Compounds in Human Breath Using High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)“. The presentation outlined how Cannabix and University of Florida researchers have made significant headway toward the development of an innovative FAIMS-based instrument for the detection of THC in human breath. PITTCON also provided Cannabix with the opportunity to cultivate strategic alliances with groups interested in advancing the implementation of breath-based drug detection for law enforcement.

Cannabix management and University of Florida chemists have confirmed the ability to specifically detect THC at standard temperature and pressure using our unique FAIMS cell coupled with mass spectrometry (FAIMS-MS). We have successfully isolated THC and THC-related by-products in controlled simulated breath samples, with the current FAIMS-MS configuration demonstrating THC detection limits which are at least 10 times more sensitive than previously reported in the exhaled breath literature. The Company also reports that it has been evaluating the feasibility of detecting other volatile compounds of interest using FAIMS-MS with promising preliminary results for cocaine models in simulated breath samples.

Development of the Cannabix instrument is rapidly advancing. Many proprietary components, such as a high-voltage generator, non-radioactive ionization source, and array detector are being integrated with the novel FAIMS cell to provide the most technologically advanced FAIMS-based instrument in the world.

Dr. Raj Attariwala, Cannabix’s Chief Scientific Officer, states, “Development of a standalone FAIMS based device for trace detection of THC in breath is progressing well. With the expertise of the Yost lab at UF, we have demonstrated the unique ability to have a device which allows real time analysis of exhaled breath without any cumbersome extraction techniques. Our recent analysis of the presentations at PITTCON affirms our belief that Cannabix is developing one of the most advanced and sensitive real time THC specific breath detection devices for roadside use by law enforcement.”

Kal Malhi, President of Cannabix stated, “Our recent visit to the University of Florida and the presentations at PITTCON reaffirm our belief that Cannabix is developing the best technology in the field of detection of THC in exhaled breath. Our FAIMS-MS device is now recognized as a very accurate and highly sensitive device and we are moving quickly towards miniaturization of the bench top device. Agreements are in place with parts suppliers and parts required to build the portable device are now on order and we expect to have a portable FAIMS-MS device for field testing in the coming months.”

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many jurisdictions globally. Cannabix is working to develop drug-testing devices that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. This technology would be used to provide detection of use of THC at the roadside to identify drivers intoxicated by the recent use of marijuana. In particular, Cannabix is focused on developing breath testing devices for THC detection that would target recent use of THC, in contrast to saliva or urine testing for THC which can be invasive and take considerable time for laboratory analysis. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

Rav Mlait, CEO

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading